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Background: Malignant hyperthermia (MH), a metabolic myopathy triggered by volatile anesthetics and
depolarizing muscle relaxants, is a potentially lethal complication of general anesthesia in susceptible patients. The
implementation of modern inhalation anesthetics that research indicates as less potent trigger substances and the
recommended limitations of succinylcholine use, suggests there may be considerable decline of fulminant MH
cases. In the presented study, the authors analyzed suspected MH episodes during general anesthesia of patients
that were referred to the Wuerzburg MH unit between 2007 and 2011, assuming that MH is still a relevant
anesthetic problem in our days.
Methods: With approval of the local ethics committee data of patients that underwent muscle biopsy and in vitro
contracture test (IVCT) between 2007 and 2011 were analyzed. Only patients with a history of suspected MH crisis
were included in the study. The incidents were evaluated retrospectively using anesthetic documentation and
medical records.
Results: Between 2007 and 2011 a total of 124 patients were tested. 19 of them were referred because of
suspected MH events; 7 patients were diagnosed MH-susceptible, 4 MH-equivocal and 8 MH-non-susceptible by
IVCT. In a majority of cases masseter spasm after succinylcholine had been the primary symptom. Cardiac
arrhythmias and hypercapnia frequently occurred early in the course of events. Interestingly, dantrolene treatment
was initiated in a few cases only.
Conclusions: MH is still an important anesthetic complication. Every anesthetist must be aware of this life-
threatening syndrome at any time. The rapid onset of adequate therapy is crucial to avoid major harm and possibly
lethal outcome. Dantrolene must be readily available wherever MH triggering agents are used for anesthesia.
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Malignant hyperthermia (MH) is mostly an inherited
subclinical myopathy triggered by volatile anesthetics
and depolarizing muscle relaxants in susceptible individ-
uals, leading to a potentially lethal hypermetabolic reaction
of skeletal muscle due to a disturbance of myoplasmic cal-
cium homeostasis. Characteristic clinical signs of MH dur-
ing a general anesthesia include hypoxemia, hypercapnia,
tachycardia, muscular rigidity, acidosis, hyperkalemia and
hyperthermia [1]. While expected genetic predisposition for
MH is stated to be as frequent as 1:2.000, the prevalence of
MH episodes varies regionally from 1:10.000 to 1:220.000* Correspondence: schuster_f@klinik.uni-wuerzburg.de
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reproduction in any medium, provided the or[2,3]. In contrast to fulminant MH episodes, abortive
courses might occur more frequently, but are difficult to
diagnose due to the alleviated symptoms.
Recent developments in anesthesiology apparently
have lead to a decrease in severe MH crisis over the last
years: Halothane, a potent MH triggering agent, is no
longer used in clinical routine in western countries [4]
and currently applied volatile anesthetics, e.g. isoflurane,
sevoflurane or desflurane, in some cases significantly
decelerate the onset of an MH reaction compared to
halothane [5,6] and are more likely to lead to abortive MH
with eased symptoms. Furthermore, the recommended
indications for succinylcholine, another possible MH trig-
gering agent, have been limited by international anesthesia
societies [7].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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study was to investigate, whether MH is still a relevant
anesthetic problem in our days.
Methods
With approval of the local ethics committee (application
number: 263/11, ethics committee of the University of
Wuerzburg) data of patients who where referred to the
MH unit of the Department of Anesthesia and Critical
Care of the University of Wuerzburg for diagnostic muscle
biopsy and subsequent in vitro contracture testing (IVCT)
between 2007 and 2011 were evaluated. Based on available
patient documents and medical records the intraoperative
events were examined. To confirm the suspicion of an
MH crisis, applied triggering agents, clinical symptoms
e.g. cardiac arrhythmia, increase of end-tidal carbon
dioxide ≥ 45 mmHg, rises of patients’ body temperature
≥ 38.5°C and possible use of dantrolene were analyzed.
Besides that, the medical records were reviewed for severe
postoperative complications, e.g. neurological deficits, dis-
seminated intravascular coagulation (DIC), acute renal
failure or signs of rhabdomyolysis according to maximum
creatine kinase (CK) levels. If blood gas analysis was
implemented, pH ≤ 7.2, base excess ≤ -5 mmol/l and
PaCO2 ≥ 50 mmHg defined a severe metabolic response.
Only patients with a suspected MH episode during general
anesthesia due to the estimation of the responsible anes-
thesiologist, completed IVCT and genetic analysis of the
ryanodine receptor gene were included in the investigation.
In referred patients a diagnostic IVCT with increasing
caffeine and halothane concentrations in separated tissue
baths was performed according to the guidelines of the
European MH Group [8]. A contracture ≥ 2 mN at caf-
feine 2 mM and halothane 0.44 mM lead to the diagnosis
MH susceptible (MHS). If significant contractures oc-
curred after one of the drugs only, patients were classified
as MH equivocal (MHE, MHE for halothane (MHEh) or
caffeine MHEc). If no significant contracture was observed
the patients were rated MH non-susceptible (MHN).
In addition, for each patient, the clinical grading scale
(CGS) by Larach and colleagues, which includes metabolic
and muscular parameters as well as changes in cardiac
rhythm and body temperature, was applied retrospectively.
According to the grading scale 3 to 15 points were cal-
culated for each parameter and added to receive a score.
This score allowed allocation to individual MH-ranks
(0 =MH almost never, 3-9 =MH unlikely, 10-19 =MH
somewhat less than likely, 20-34 =MH somewhat
greater than likely, 35-49 =MH very likely, > 50 =MH
almost certain) [9].
Results
Between 2007 and 2011 a total of 124 patients underwent
a muscle biopsy followed by IVCT at the MH lab of theUniversity of Wuerzburg. Overall 19 of these patients had
been referred to the MH unit because of a suspected MH
event during general anesthesia on the basis of estimation
of the attending anesthesiologists. In the remaining pa-
tients MH diagnostics were initiated due to MH suscepti-
bility in the family history, an unexplained rhabdomyolysis
or to exclude a myopathic disorder in association with
persistently elevated CK levels.
Diagnostic findings
Muscle biopsy and IVCT detected MH susceptibility in 7
(37%; 7 male) of the 19 patients. In 8 patients (42%; 3
male, 5 female) MH susceptibility could be excluded.
Muscle bundles of 4 patients (21%; 1 male, 3 female)
developed a pathologic contracture only after exposure to
halothane but not after caffeine (MHEh). Interestingly, ini-
tial applied CGS rated the probability of an MH crisis as
“almost certain” (> 50 points) in 2 MHS patients and “very
likely” (35 – 49 points) in 5 MHS and 1 MHEh patients,
while in 3 MHEh patients the likelihood was classified as
“less than likely” (10 - 19 points). Noteworthy, MH was
assumed “greater than likely” (20 – 34 points) in 6 MHN
patients and “less than likely” or “almost never” in 1 MHN
patient each by CGS. Genetic screening detected muta-
tions in the ryanodine receptor gene (Gly4037Alafs,
Glu2174Ala, Val4234Leu) of 3 MHS patients. In 16 (84%)
patients the suspected MH event occurred between 2006
and 2010 (6 MHS, 3 MHEh, 7 MHN). The remaining 3
patients had been 10 years old or younger at the time of
incident (1992, 1995, 1998) and therefore muscle biopsy in
these patients was delayed until the age of 16 years
according to our hospital standard operating procedures.
Since the MH diagnostic was performed within the study
period, these 3 patients were included in the evaluation,
even if the applied triggers were halothane or enflurane re-
spectively. Interestingly, 2 MHS individuals with suspected
MH in their history had undergone at least one uneventful
general anesthesia in the past. The histopathological ex-
aminations revealed a myopathic tissue syndrome in com-
bination with cell clumps indicating a possibly neurogenic
component in 1 MHEh patient, who had received suc-
cinylcholine as sole trigger agent. In the other patients
there was no evidence of a muscular pathology (Table 1).
Trigger agents and clinical presentations
Only 21% of the MH suspected patients solely received
an inhalation anesthetic (sevoflurane: 1 MHS; isoflurane:
1 MHN; desflurane: 2 MHN), while in 47% of the cases
(6 MHS, 1 MHEh, 2 MHN) a combination of succinylcho-
line with a volatile anesthetic, e.g. halothane (1 MHEh), en-
flurane (1 MHN) isoflurane (3 MHS, 1 MHN), sevoflurane
(2 MHS) or desflurane (1 MHS) was used. In 28%
(3 MHEh, 3 MHN) succinylcholine was applied as only
MH trigger. Masseter spasm was observed in 63% of the
Table 1 Diagnostic findings
No Age/sex IVCT Year of incidence Surgery Prev. Anesth. Genetic status CGS Histopathology
1 46 ♂ MHS 2010 Liposuction 1 Negative 48 WPF
2 58 ♂ MHS 2010 Spongiosaplasty 2 Gly4037Alafs 38 WPF
3 36 ♂ MHS 2010 Urachal fistula - Negative 43 WPF
4 14 ♂ MHS 2009 Lower leg fracture - Glu2174Ala 53 WPF
5 18 ♂ MHS 2008 Gunshot injury - Val4234Leu 53 WPF
6 45 ♂ MHS 2007 Hemilaminectomy - Negative 38 WPF
7 10 ♂ MHS 1995 Appendectomies - Negative 40 WPF
8 62 ♀ MHEh 2009 Bursectomy - Negative 15 WPF
9 32 ♀ MHEh 2009 Caesarean section - Negative 40 Myopathy
10 29 ♀ MHEh 2006 Uterine abrasion - Negative 15 WPF
11 3 ♂ MHEh 1992 Tonsillectomy - Negative 18 WPF
12 35 ♀ MHN 2011 Uterine abrasion 2 Negative 18 WPF
13 54 ♂ MHN 2010 Aortocoronary bypass - Negative 30 WPF
14 46 ♀ MHN 2009 Uterine abrasion 1 Negative 30 WPF
15 34 ♀ MHN 2008 Colon resection - Negative 25 WPF
16 57 ♀ MHN 2007 Inguinal hernia - Negative 30 WPF
17 21 ♀ MHN 2007 Mandible fracture - Negative 0 WPF
18 39 ♂ MHN 2006 Appendectomies - Negative 30 WPF
19 3 ♂ MHN 1998 Orchidopexy - Negative 30 WPF
Age Patients’ age MH-suspected episode occurred, IVCT In vitro contracture test, ♂ Male, ♀ Female, MHS Malignant hyperthermia susceptible, MHN Malignant
hyperthermia non-susceptible, MHEh Malignant hyperthermia equivocal to halothane, WPF Without pathological finding.
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the cases (3 MHEh, 3 MHN) after succinylcholine
administration. Based on the available patient records,
application of volatile anesthetics or succinylcholine
was stopped in all of the 19 patients and anesthesia was
continued intravenously.
Cardiac arrhythmias were reported in 42% of the 19
cases. Hereof, an unexplained sinus tachycardia with heart
rates between 90 to 135 per minutes were documented in
38% of the patients (3 MHS), while in 62% (2 MHS,
1 MHEh, 2 MHN) tachyarrhythmia were observed.
In 11% of the patients, who received sevoflurane (1 MHS)
or succinylcholine (1 MHEh) solely no arrhythmias were
seen. In the remaining suspected cases the cardiac rhythm
was not documented in patients’ medical records. An
increase of end-tidal carbon dioxide > 45 mmHg during
the course of anesthesia was noticed in 42% (5 MHS,
3 MHN). However, body temperature increases ≥ 38.5°C
were only reported in 11% of the analyzed cases (1 MHS,
1 MHN). In 47% of the MH suspected cases (7 MHS,
1 MHEh, 1 MHN) an increase of CK levels > 10.000 U/L
following MH trigger application was observed. Despite
the suspected MH diagnosis, dantrolene was administered
only in 37% (5 MHS, 1 MHEh, 1 MHN) for treatment of
the observed symptoms (Table 2).
According to the medical records of the referred pa-
tients, no persistent or temporary complications e.g. DIC,acute renal failure or neurological deficits were reported
during recovery after the suspected MH episode.
Blood gas analysis
Interestingly, in only 37% of the patients with suspected
MH event an arterial blood gas analysis was documented
to verify the assumed MH diagnosis. However, a relevant
metabolic acidosis with pH ≤ 7.2, base excess ≤ -5 mmol/l
and PaCO2 ≥ 50 mmHg was observed in 21% (3 MHS,
1 MHN). Besides that, serum potassium levels were re-
markable elevated ≥ 5 mmol/l in 16% of the cases (2 MHS,
1 MHN) (Table 3).
Discussion
Even though MH is a rare complication of general
anesthesia, the presented cases clearly demonstrate that
this life threatening muscular hypermetabolism is still a
relevant risk requiring immediate and consequent treat-
ment by the responsible anesthesiologist to avoid serious
harm to the patient.
After the first description of MH by Denborough nu-
merous cases of fulminant MH as well as in vitro inves-
tigations had been published in the following years,
identifying halothane and succinylcholine as potential
MH triggering agents [10]. While the metabolic deterior-
ation in the course of an MH crisis induced by halothane
seems to be a direct consequence of an interaction with
Table 2 Applied trigger agents and clinical presentations of malignant hyperthermia suspected events
No IVCT Trigger agents Masseterspasm Dantrolene
application
Cardiac
arrhythmia
Max. end-tidal
CO2 [mmHg]
Max. temperature Max. Creatine
kinase [U/L]
1 MHS Isoflurane + SCh Unknown 1 × 200 mg Sinus
tachycardia
48 mmHg 38.8°C 10.514
2 MHS Isoflurane + SCh Yes 1 × 240 mg Tachyarrhythmia 54 mmHg 36.1°C > 10.000
3 MHS Sevoflurane + SCh Yes No Sinus
tachycardia
Unknown Unknown 51.557
4 MHS Sevoflurane + SCh Unknown 2 × 200 mg Sinus
tachycardia
62 mmHg Unknown 23.700
5 MHS Desflurane + SCh Unknown 1 × 220 mg Tachyarrhythmia 56 mmHg 37.6°C ≈ 80.000
6 MHS Sevoflurane No 1 × 200 mg No 85 mmHg 37.5°C 38.762
7 MHS Isoflurane + SCh Unknown No Unknown Unknown Unknown 16.412
8 MHEh SCh Yes 1 × 200 mg Unknown 39 mmHg Unknown 119.150
9 MHEh SCh Yes Unknown No 36 mmHg Unknown 162
10 MHEh SCh Yes No Unknown Unknown Unknown 2.234
11 MHEh Halothane + SCh Yes Unknown Tachyarrhythmia Unknown Unknown Low
12 MHN SCh Yes No Tachyarrhythmia Unknown Unknown 132
13 MHN Isoflurane Yes No Unknown 54 mmHg Unknown 4.100
14 MHN SCh Yes No Unknown Unknown Unknown 24.732
15 MHN Desflurane No 1 × 180 mg Tachyarrhythmia 72 mmHg Unknown Unknown
16 MHN SCh Yes No Unknown Unknown Unknown Unknown
17 MHN Desflurane No No Unknown Unknown 38,5°C Unknown
18 MHN Isoflurane + SCh Yes No Unknown 41 mmHg Unknown 5.174
19 MHN Enflurane + SCh Yes No Unknown 75 mmHg Unknown 4.820
IVCT In vitro contracture test, MHS Malignant hyperthermia susceptible, MHN malignant hyperthermia non-susceptible, MHEh Malignant hyperthermia equivocal to
halothane, SCh Succinylcholine, CO2 Carbon dioxide.
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mode of action of succinylcholine has remained unknown.
For instance, in vitro succinylcholine increased halothane-
induced muscular contractions of MHS patients, but no
contracture could be observed after exposition to succinyl-
choline alone [11]. Even systemic application of succinyl-
choline could not reproducibly elicit an MH episode in
susceptible swine [12,13]. In humans, according to an
evaluation of the North American MH Registry and aTable 3 Blood gas analysis of malignant hyperthermia
suspected events
No IVCT pH BE [mmol/l] PaCO2 [mmHg] Potassium [mmol/l]
1 MHS 7.20 - 50 -
3 MHS 7.19 −7 55 3.9
5 MHS* 7.38 1 46 6.3
10 MHS 7.17 −3,8 72 5.0
15 MHN 7.20 −7,9 69 7.3
17 MHN 7.30 - 38 4.1
19 MHN 7.30 - - -
IVCT In vitro contracture test, MHS Malignant hyperthermia susceptible, MHN
Malignant hyperthermia non-susceptible, BE Base excess, PaCO2 Arterial
carbon dioxide pressure.
*blood gas analysis after admission at the intensive care unit.recently performed European multicentric study, succinyl-
choline triggered MH in absence of an inhalation
anesthetic only in 0.7% or 1% respectively of the investi-
gated cases [14,15]. Since the definitively underlying mode
of action of succinylcholine to elicit MH remains unclear
so far, the pharmacological characteristics of this agent
may enable a possible explanation of it’s role to induce
MH. Following intravenous application succinylcholine
activates the nicotinergic acetylcholine receptor and pro-
vokes a local depolarization of the cell membrane. The
transient depolarization of voltage-gated receptors in
combination with an influx of extracellular calcium via
acetylcholine receptors could lead to a significant increase
of intracellular calcium concentrations and after exceeding
a certain threshold MH may occurs in affected individuals.
In this context, muscular fasciculation and rigidity caused
by succinylcholine was considered to be causal for MH.
Consequently, a masseter spasm following succinylcholine
was postulated to be an early sign of an imminent MH
episode. However, specificity of this clinical sign is limited
due to the subjective appraisal and the fact, that jaw tight-
ness is a common side effect of succinylcholine, but only
in half of the patients associated with MH susceptibility
[16]. Similar results were obtained in our investigation.
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suspected MH cases, where a succinylcholine-induced
masseter spasm was noticed. Interestingly, histological
examination of 1 MHEh patient who solely received suc-
cinylcholine revealed suspected myopathological finding.
Although, neuromuscular disorders are common in MHE
patients [17], it remains unclear, if these muscular alter-
ations were responsible for the increased sensitivity to
succinylcholine in this patient.
Generally, the likelihood of succinylcholine-induced
MH seems to be extremely low, however there is little
doubt, that combination with a volatile anesthetic potenti-
ates the onset and the clinical symptoms of an MH event
[18]. Remarkably, despite the possibly serious side-effects
like MH, hyperkalemia or cardiac arrest, succinylcholine
was actually applied to secure the airway in 79% of the
referred patients. In part, this approach was reasonable
due the higher risk of aspiration in case of trauma or
abdominal surgery. However, according to published
guidelines the use of the non-depolarizing muscle relax-
ant rocuronium and if needed followed by application
of sugammadex to reverse the neuromuscular blockade
might be an adequate alternative to avoid succinylcho-
line associated adverse effects [7,19].
In contrast to succinylcholine, the impact of all inhal-
ation anesthetics used in daily clinical routine in the de-
velopment of an MH crisis is beyond dispute. However,
dependent on the applied volatile anesthetic the time
interval between induction of anesthesia and clinical
symptoms of an MH episode seems to vary. For instance,
Hopkins and colleagues reported, that in susceptible
patients the onset of MH was statistically significant
faster after halothane exposure compared to enflurane
or sevoflurane [5]. Equally, fulminant MH episodes
after isoflurane, sevoflurane or desflurane seem to
occur with temporal delay [20,21], while halothane
may induce MH within minutes [5]. In MHS animals,
similar results were seen after intramuscular injection of
halothane or sevoflurane. The induced local hypermetabolic
responses measured by local muscular lactate and car-
bon dioxide pressure increase were more distinct after
halothane than after sevoflurane application [22,23].
Furthermore, in vitro the effect on muscular contrac-
tures of MHS muscle bundles varies between halothane
and modern volatile anesthetics at equivalent concen-
trations [24]. These different clinical appearances of
MH following volatile anesthetic application might be
caused due to differences in the calcium releasing po-
tency of these diverse agents. For example, sarcoplasmic
calcium release at cellular level was significant smaller
after sevoflurane or desflurane exposure compared to
equimolar halothane concentrations [25,26]. In the ana-
lyzed anesthetic events of the present evaluation, MH
episodes were induced by established MH triggers likehalothane or isoflurane as well as by modern volatile
anesthetics, e.g. sevoflurane or desflurane. Although, in
the majority of the cases inhalation anesthetics were
combined with succinylcholine and only in one case
sevoflurane was applied solely, our findings emphasized
the MH trigger potency of newer volatile anesthetics.
Beside masseter spasm cardiac arrhythmias are further
early symptoms of imminent MH. Equally to a retrospect-
ive analysis from the United States, where the incidence
was estimated 40% [14], in the presented investigation the
occurrence of unexplained cardiac alterations was 42%.
On closer examination the incidence of cardiac symptoms
was even higher in the MHS group with either sinus
tachycardia or tachyarrythmia as the leading signs.
The low incidence of testified metabolic acidosis might
be attributed to the failure to obtain arterial blood gas ana-
lysis in the acute phase of the MH reaction or due to
dantrolene pretreatment. For example, one patient’s blood
gas analysis was performed not until the arrival on the
intensive care unit and after treatment with dantrolene,
showing an unremarkable blood acid status, while in con-
trast the intraoperative end-tidal carbon dioxide increased
relevant to 56 mmHg in this patient. Overall, in only 37%
of the MH suspected cases a blood gas analysis was
conducted to verify the suspected diagnosis. This line of
action is remarkable, since the presence of an acidosis
supports the reasonable suspicion of MH in these cases.
Hyperthermia is a dramatic but often late sign of MH,
reflecting the proceeding metabolic breakdown in affected
individuals. Hence, temperature monitoring during gen-
eral anesthesia is recommended if MH triggers are used,
since in a couple of cases hyperthermia was the only sign
of MH [14]. Fulminant MH episodes may be marked by a
rapid increase in body temperature at a rate of 1-2°C every
five minutes [27]. Stunningly, only in 11% of the suspected
MH cases (1 MHS and 1 MHN) a remarkable hyperther-
mia with an increase in core temperature ≥ 38.5°C was no-
ticed. The overall low incidence of core temperature rises
in the presented study might be attributable to the initi-
ated dantrolene treatment or the possible absence of
temperature monitoring.
The pathological changes during MH crisis are based
on an uncontrolled increase of myoplasmic calcium,
resulting in an ongoing skeletal muscular contracture
and loss of cellular integrity leading to hyperkalemia
and rhabdomyolysis [28]. Although the surgical trauma
itself might cause a significant increase in CK levels,
postoperative unexplained excessive hyperCKemia should
lead to a diagnostic workup to exclude MH susceptibility
as underlying pathology. The reason for the remarkable
CK increase up to 24.732 U/L in one of the MHN
patients following succinylcholine remains unclear. A
not yet diagnosed myopathy could not definitely be ex-
cluded, but based on the advanced age of the patient
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very unlikely.
In contrast to the estimation, that nearly 70% of MH
families carry mutations in the ryanodine receptor gene
[29], the genetic prevalence of 27% in the analyzed MHS
cases was overall low. Noteworthy, even if the Val4234Leu
variant of one MHS patient has recently been mentioned
in context of a novel exome sequencing method for MH
relevant mutations [30], none of the detected genetic vari-
ants had been accepted as causative for MH according to
the European MH Group database, which includes so far
31 approved mutations of the more than 200 identified
ryanodine receptor gene variants [31]. However, it is im-
portant to mention, that absence of a causative mutation
does not reliably exclude MH susceptibility. To confirm or
exclude MH a muscle biopsy followed by an IVCT must
be carried out in these patients [32].
After introduction of dantrolene in clinical use a
causal treatment of MH has been available since the late
1970’s. The mode of action of this drug is based on in-
hibition of the sarcoplasmic reticulum calcium release
without increasing the reuptake of calcium ions into the
sarcoplasmic reticulum [33]. According to current guide-
lines application of dantrolene is an essential part in the
treatment of an MH crisis [34,35]. However, only 37% of
the patients in the presented investigation received
dantrolene for causal MH therapy. Nevertheless, the im-
portance of consequent dantrolene treatment is absolutely
clear [36], even if the hypermetabolic state in some of the
presented cases was already terminated by discontinuation
of MH trigger substances.
Once surviving fulminate MH episodes several reports
documented severe complications, e.g. acute renal failure
from rhabdomyolysis, DIC, congestive heart failure or
intestinal ischemia due to the uncontrolled metabolic
reaction and myocyte death [27]. Fortunately, the review
of the medical records of the referred patients, did not
detect any serious harms to the patients after an MH
episodes, which importantly delayed recovery.
To draw conclusions about the likelihood of MH among
the suspected incidents, the “Clinical Grading Scale”
(CGS) established by Larach and colleagues assessed
clinical and metabolic parameters, e.g. muscle rigidity,
rhabdomyolysis, acidosis, increases in body temperature
and cardiac arrhythmias [9]. The validity of the CGS may
be reduced due to limited availability of complete data sets
and hence, often does not satisfactorily correlate with the
IVCT results [37]. The false negatives as well as the false
positive diagnosis obtained by CGS calculation in our ana-
lysis are likely a result of the fragmentary available medical
records. Thus, sole evaluation of the CGS seems not to be
adequate to prove MH susceptibility.
Finally, anesthesiologists must be aware that unevent-
ful previous general anesthesia does not exclude MHsusceptibility [14]. For instance, two of the MHS pa-
tients reported a history of exposure anesthesia in the
past. The reason why some patients develop MH after
first exposition to MH triggering agents, while others
do not, still remains unclear and might be explained by an
individual cellular compensation mechanism lowering
myoplasmic calcium concentrations.
Conclusions
Analysis of the presented data might be limited by partly
incomplete documentation as well as the individual inter-
pretation. Nevertheless, in conclusion MH still is a rele-
vant complication these days and every anesthesiologist
must be prepared to recognize the symptoms of MH crisis
and to start sufficient treatment. While fulminate courses
of MH are easy to diagnose, abortive presentations with
solitary or alleviated symptoms are more difficult to detect
and pose an enormous challenge to the attending an-
esthesiologist. The initiation of an adequate and conse-
quent treatment including the application of dantrolene
and termination of MH trigger application is essential for
patients’ prognosis and survival. Besides that, every patient
after a suspected MH event should be referred to a MH
center for further counseling.
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